Image Not Found
Investment Growth with Portfolio Balance and Risk Management
info@merciafund.co.uk

  • About Us

    Mercia Fund Management is a venture capital fund manager with over £17 million under active management. We provide investment capital to businesses seeking early stage (via Mercia Fund 1 which is partnered with eight universities), expansion and development capital to unquoted cash generative UK based companies. Click here for more.

    • News

    If you wish to receive automatic updates on Mercia Fund Management news items, please subscribe to our RSS feed by clicking on and following the on-screen instructions.

    Shell Springboard regional winner Ventive secures £900,000 funding

    May 9, 2013

    Henley-in-Arden, 9 May 2013 – Venture capital fund manager Mercia Fund Management (MFM) has participated in an equity raise of more than £900,000 for Ventive [...]

    Dr Christine Wilkinson Blanc joins Psioxus Therapeutics as Chief Medical Officer

    May 8, 2013

    Experienced CMO to Oversee and Advance Clinical Oncology and Cachexia Programs OXFORD, UK – 8th May 2013 – PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage [...]

    Mercia Fund Management announces Carlton Jones as nanoTherics’ CEO

    April 15, 2013

    Henley-in-Arden, 15 April 2013 – Venture capital fund managers Mercia Fund Management (MFM) and Catapult Venture Managers have announced the appointment of Carlton Jones as [...]

    Mercia Fund Management announces first SEIS investments from the Mercia Growth Fund 1

    April 9, 2013

    Open House event seeks to identify innovative start-ups looking for funding Henley-in-Arden, 09 April 2013. Venture capital fund manager Mercia Fund Management (MFM) has announced [...]

    Oxford’s Native Antigen Company receives funding boost

    April 4, 2013

    Urges start-ups to attend Mercia Fund Management Open House Oxford, 2 April 2013. Oxford-based The Native Antigen Company (NAC) has received new investment from the [...]

    Sarissa Biomedical is developing a range of minimally invasive, microelectrode electrochemical sensors for the measurement of the purines and other neurochemicals, as indicators of neurological activity/disorders. Circadian Solar is a leading developer of concentrated photovoltaic technology, a form of solar power that unlocks the potential of the sun to deliver clean, renewable and affordable energy. Celentyx Ltd is a pharmaceutical research and development company that uses a novel technology called Novel Clinical Identification Profiling™ to assess the suitability of existing drugs in the treatment of new illnesses. Allinea Software specialises in developing software tools designed to ensure that applications can run problem-free on parallel computing systems. LM Technologies are developing innovative wireless products including the world’s smallest Bluetooth adapter. Intelligent Orthopaedics specialises in the design and development of products for treating orthopaedic trauma. nanoTheric's patented technology uses nanoparticles and magnetic fields to facilitate the delivery of molecules such as DNA into living cells. Nightingale EOS has developed laser-based technology called Beam Profile Reflectometry which is able to measure the characteristics of the thin coatings applied to medical implants such as cardiac stents and replacement joints. Anaxsys is a cutting edge sensor technology company that is developing a range of respiratory diagnostic and monitoring products based upon their unique sensor technology. Warwick Audio Technologies has developed a radically new type of mid-range loudspeaker that is ultra-thin, lightweight, flexible and inexpensive to manufacture.

  • Latest News

  • Search

  • Sign up for our mailing list.

  • Follow us on LinkedIn

    • Mecia Fund Managament Ltd (registered in England No. 06973399) is authorised and regulated by the Financial Conduct Authority in the conduct of its Investment Business